ACP
IMGN

Acuta Capital Partners’s Immunogen Inc IMGN Stock Holding History

Acuta Capital Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-140,000
Closed -$669K – 51
2022
Q3 		$669K Buy
+140,000
New +$738K 0.29% 36
2022
Q2 		– Sell
-55,000
Closed -$262K – 51
2022
Q1 		$262K Buy
+55,000
New +$305K 0.12% 38

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Acuta Capital Partners's IMGN Position: Q4 2022 in Review

Acuta Capital Partners sold out of Immunogen Inc (IMGN) in Q4 2022, closing a stake of 140,000 shares — an estimated $669K sold.

Acuta Capital Partners first reported a position in IMGN in Q1 2022 and held it in 2 quarters. The position peaked at $669K in Q3 2022. 204 funds tracked by Wall St. Rank hold IMGN as of Q4 2022.

  • Acuta Capital Partners reported no remaining Immunogen Inc position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 140,000 Immunogen Inc shares in Q4 2022, an estimated $669K.
  • Acuta Capital Partners first reported a position in Immunogen Inc in Q1 2022 and held it in 2 quarters.
  • Acuta Capital Partners's Immunogen Inc position peaked at $669K in Q3 2022.
  • 204 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.